Now showing items 1-6 of 6
Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria in Uganda
(Public Library of Science, 2006-05)
Objectives: To compare the efficacy and safety of artemisinin combination therapies for the treatment of uncomplicated falciparum malaria in Uganda. Design: Randomized single-blind controlled trial. Setting: Tororo, Uganda, ...
Complexity of plasmodium falciparum infections and antimalarial drug efficacy at 7 sites in Uganda.
(University of Chicago Press, 2006-03-13)
Malaria infections in Africa frequently include multiple parasite strains.We examined the relationship between the number of infecting Plasmodium falciparum strains and the responses to 3 different combination therapies ...
Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda
(Public Library of Science, 2008-06)
Background: Uganda recently adopted artemether-lumefantrine (AL) as the recommended first-line treatment for uncomplicated malaria. However, AL has several limitations, including a twice-daily dosing regimen, recommendation ...
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial.
Objectives: To compare the efficacy and safety of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) for treating uncomplicated falciparum malaria in Uganda. Design: Randomized single-blinded clinical ...
Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study.
(University of Chicago Press, 2005-11-18)
Background. Human immunodeficiency virus (HIV) infection may increase the burden of malaria by increasing susceptibility to infection or by decreasing the response to antimalarial treatment. We investigated the seroprevalence ...
Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis
(BioMed Central, 2009-08-23)
Background: Artesunate and amodiaquine (AS&AQ) is at present the world's second most widely used artemisinin-based combination therapy (ACT). It was necessary to evaluate the efficacy of ACT, recently adopted by the World ...